Racura Oncology (ASX:RAC) Forward PE Ratio: 0.00 (As of Jul. 09, 2026)


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.14
View Full Analysis

What is Racura Oncology Forward PE Ratio?

Racura Oncology ASX:RAC +0.94% 31 Forward PE Ratio is 0.00 as of Jul. 09, 2026. GuruFocus rates ASX:RAC with a GF Score™ of 31/100. Among 354 Biotechnology companies, Racura Oncology ranks worse than 282485.59% on this metric.

Racura Oncology's Forward PE Ratio for today is 0.00.

Racura Oncology's PE Ratio without NRI for today is 0.00.

Racura Oncology's PE Ratio (TTM) for today is 0.00.

Racura Oncology  (ASX:RAC) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Racura Oncology Forward PE Ratio Related Terms

Racura Oncology Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Racura Oncology's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Forward PE Ratio Chart

Racura Oncology Annual Data
Trend
Forward PE Ratio

Racura Oncology Semi-Annual Data
Forward PE Ratio

ASX:RAC vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Racura Oncology's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Racura Oncology Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Racura Oncology's Forward PE Ratio falls into.


ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Racura Oncology (ASX:RAC) has a Forward PE Ratio of 0.00 as of Jul. 09, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #999999 out of 354 companies in the Biotechnology industry.
Is Racura Oncology's Forward PE Ratio too high?
Racura Oncology's current Forward PE Ratio is 0.00. Based on the distribution chart, Racura Oncology ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #999999 out of 354 companies for Forward PE Ratio. This places Racura Oncology in the lower half of its industry. The industry median Forward PE Ratio is 22.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.12, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Racura Oncology and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Forward PE Ratio is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.14
Price